ebola
viru
ebov
envelop
singlestrand
negativesens
rna
viru
order
mononegaviral
along
marburg
viru
marv
form
filoviru
famili
ebov
etiolog
agent
ebola
hemorrhag
fever
ehf
highli
lethal
hemorrhag
fever
mortal
sinc
discoveri
ebov
caus
sporad
outbreak
subsaharan
africa
death
toll
hundr
interestingli
filovirus
recent
discov
one
nonretroviru
rna
paleovirus
identifi
mammalian
genom
suggest
ancient
relationship
mammal
grow
evid
suggest
bat
natur
reservoir
ebov
wild
today
current
treatment
ebola
hemorrhag
fever
pure
support
lack
effect
intervent
underscor
import
develop
broadlyprotect
vaccin
confer
longlast
immun
abil
develop
vaccin
critic
depend
understand
mechan
ebov
suppress
distract
otherwis
evad
host
immun
respons
one
wide
hypothes
immun
evas
mechan
employ
ebola
viru
secret
truncat
viral
glycoprotein
ebov
infect
cell
ebov
surfac
glycoprotein
mediat
host
cell
attach
fusion
primari
structur
compon
expos
viru
surfac
reason
focu
ebov
vaccin
research
gener
accept
robust
antibodi
respons
crucial
protect
lethal
ebov
challeng
ebov
form
trimer
spike
virion
surfac
similarli
influenza
ha
hiv
env
also
like
ha
env
gp
first
synthes
uncleav
precursor
cleav
golgi
complex
proteas
furin
two
function
subunit
ntermin
subunit
contain
put
receptorbind
domain
rbd
ctermin
subunit
contain
fusion
apparatu
transmembran
domain
encod
two
disjoint
read
frame
viru
genom
two
read
frame
join
togeth
slippag
viral
polymeras
edit
site
tract
insert
gener
mrna
transcript
allow
readthrough
translat
howev
transcript
edit
remain
unedit
transcript
prematur
stop
codon
result
synthesi
truncat
glycoprotein
product
sgp
secret
larg
quantiti
extracellular
space
though
product
conserv
ebov
speci
consider
debat
regard
function
sgp
unlik
sgp
form
homodim
appear
intrins
antiinflammatori
activ
recent
find
ebov
quickli
mutat
synthes
primarili
cell
cultur
mutant
viru
revert
primarili
sgpproduc
phenotyp
vivo
suggest
import
role
sgp
viru
surviv
within
host
sgp
share
sequenc
ntermin
region
initi
hypothes
sgp
function
decoy
antibodi
earli
effort
identifi
activ
yield
mix
result
observ
antibodi
often
crossreact
sgp
cast
doubt
hypothesi
furthermor
recent
studi
demonstr
immun
elicit
antibodi
larg
epitop
share
sgp
howev
studi
investig
monoclon
antibodi
anim
immun
vaccin
contain
express
primarili
repres
state
natur
infect
note
one
earli
studi
examin
monoclon
antibodi
mice
immun
venezuelan
equin
enceph
replicon
produc
sgp
found
mani
antibodi
crossreact
sgp
monoclon
antibodi
isol
human
ehf
survivor
shown
preferenti
react
sgp
studi
suggest
sgp
may
play
import
role
alter
host
antibodi
respons
studi
demonstr
sgp
induc
host
antibodi
respons
focus
epitop
share
therebi
allow
bind
compet
antibodi
describ
mechan
term
antigen
subvers
distinct
previous
propos
decoy
mechan
secret
glycoprotein
simpli
passiv
absorb
antiglycoprotein
antibodi
importantli
demonstr
sgp
also
subvert
exist
immun
respons
weakli
crossreact
sgp
antigen
subvers
repres
novel
host
immun
evas
mechan
import
implic
ebov
vaccin
design
may
shed
light
viru
surviv
natur
reservoir
first
gener
ebov
gp
construct
individu
express
sgp
natur
infect
ebov
direct
synthesi
sgp
differenti
edit
mrna
transcript
fig
howev
observ
dnadepend
rna
polymeras
ddrp
edit
effici
ebov
rna
polymeras
furthermor
addit
polymeras
slippag
possibl
edit
site
also
serv
prematur
polyadenyl
signal
well
ribosom
slippag
signal
thu
gener
panel
ebov
gp
edit
site
mutant
order
control
level
sgp
express
fig
made
insert
wild
type
edit
site
result
domin
gene
product
silent
mutat
introduc
edit
site
ablat
transcript
slippag
result
express
sole
gene
product
mutat
also
introduc
gener
sgpedit
express
sgp
sole
gene
product
construct
subclon
mammalian
express
vector
pcagg
protein
express
examin
hela
cell
fig
cell
data
shown
cell
transfect
express
intracellularli
surfac
secret
supernat
previous
character
tacedepend
cleavag
interestingli
produc
higher
amount
sgpedit
express
high
level
sgp
secret
effici
supernat
express
undetect
like
minim
ddrpmediat
edit
express
experi
demonstr
mutat
edit
site
signific
effect
gp
express
next
investig
immunogen
edit
site
mutant
dna
vaccin
femal
balbc
mice
immun
sgpproduc
construct
fig
mice
immun
sgpedit
construct
develop
similar
titer
antibodi
measur
elisa
mice
immun
develop
fourfold
higher
titer
antibodi
fig
mice
immun
construct
express
predominantli
sgp
sgpedit
develop
much
higher
titer
antisgp
antibodi
mice
immun
construct
express
predominantli
fig
shown
fig
mice
develop
much
higher
titer
antibodi
sgpbind
antibodi
hand
sgpimmun
mice
develop
much
higher
titer
sgpbind
antibodi
antibodi
despit
fact
sgp
share
roughli
linear
sequenc
result
suggest
sgpimmun
anim
either
mani
sgpbind
antibodi
direct
conform
epitop
share
direct
share
epitop
inaccess
given
anim
immun
sgp
develop
antibodi
preferenti
bind
differ
gp
isoform
perform
western
blot
analysi
determin
differ
linear
epitop
target
antibodi
versu
sgpimmun
mice
shown
fig
antisera
mice
react
strongli
weakli
sgp
hand
antisera
sgpimmun
mice
react
strongli
sgp
weakli
suggest
linear
epitop
target
antibodi
mice
unshar
sgp
investig
whether
sgpbind
antibodi
immun
mice
crossreact
two
gp
isoform
separ
popul
antibodi
perform
competit
elisa
determin
sgp
could
compet
antibodi
fig
similar
western
blot
data
sgp
unabl
compet
bind
antibodi
immun
mice
fig
hand
sgp
abl
effici
compet
antibodi
sgpimmun
mice
expect
abl
compet
group
fig
furthermor
observ
ident
reactiv
pattern
nativ
membraneanchor
ebov
use
cell
surfac
competit
elisa
supplement
fig
examin
abil
two
gp
isoform
compet
antibodi
perform
competit
immunoprecipit
purifi
presenc
sgp
vari
molar
ratio
immunoprecipit
antiserum
sgpimmun
mice
analyz
western
blot
use
polyclon
rabbit
antibodi
react
gp
isoform
antiserum
mice
precipit
sgp
increas
concentr
sgp
attenu
amount
signal
fig
suggest
presenc
two
separ
popul
antibodi
crossreact
sgp
howev
antiserum
sgpimmun
mice
also
precipit
sgp
increas
concentr
sgp
significantli
attenu
amount
precipit
fig
indic
antibodi
mice
crossreact
sgp
control
addit
recombin
ha
effect
amount
precipit
either
antiserum
group
taken
togeth
data
suggest
antibodi
induc
direct
primarili
epitop
share
sgp
wherea
antibodi
induc
sgp
direct
epitop
share
sgp
investig
whether
differ
abil
antisera
immun
group
neutral
ebov
viru
infect
whether
sgp
could
interfer
antibodymedi
neutral
pseudovirus
gener
use
envdefici
hiv
backbon
pseudotyp
zair
ebov
order
achiev
consist
neutral
pool
sera
four
highest
respond
among
anim
among
sgpimmun
anim
antisera
group
abl
effect
neutral
pseudovirus
measur
luciferas
report
assay
fig
although
antisera
mice
exhibit
potent
neutral
activ
antisera
sgpimmun
mice
probabl
due
higher
overal
titer
determin
sgp
interfer
neutral
use
antiserum
dilut
correspond
neutral
activ
group
preincub
antisera
differ
amount
sgp
consist
competit
elisa
result
sgp
abl
complet
attenu
neutral
activ
antisera
sgpimmun
mice
effect
neutral
activ
antisera
mice
fig
purifi
influenza
ha
use
control
effect
neutral
activ
either
antiserum
group
similar
result
observ
use
antiserum
dilut
correspond
neutral
activ
supplement
fig
data
confirm
sgp
compet
antibodi
interfer
antibodymedi
neutral
anim
expos
sgp
inabl
sgp
compet
antibodi
mice
intrigu
consid
share
almost
half
ectodomain
sequenc
sgp
reason
antibodi
may
direct
sole
epitop
share
sgp
antibodi
may
direct
share
epitop
preferenti
bind
conform
differ
two
gp
isoform
result
tertiari
quarternari
structur
steric
shield
address
possibl
use
quantiti
elisa
determin
rel
titer
estim
averag
affin
antibodi
sgpimmun
anim
sgp
individu
examin
purifi
polyclon
igg
five
highest
respond
sgpimmun
group
calcul
appar
dissoci
constant
kd
antisgp
antibodi
appar
kd
calcul
scatchard
analysi
describ
elsewher
repres
estim
averag
affin
antigp
antibodi
lower
appar
kd
correpond
higher
averag
affin
consist
elisa
data
fig
mice
immun
higher
titer
antibodi
antisgp
antibodi
fig
howev
measur
differ
appar
kd
vs
sgpbind
antibodi
fig
indic
preferenti
bind
antibodi
anim
due
affin
differ
differ
gp
isoform
mice
immun
sgp
observ
high
titer
antisgp
antibodi
low
level
antibodi
howev
antibodi
bind
appear
modestli
lower
kd
higher
averag
affin
sgpbind
antibodi
fig
futur
studi
monoclon
antibodi
direct
epitop
share
sgp
provid
inform
whether
specif
antibodi
bind
two
gp
isoform
differ
affin
nonetheless
present
data
provid
evid
differ
affin
respons
antibodi
sgpimmun
mice
react
preferenti
differ
gp
isoform
secret
surfac
glycoprotein
mechan
absorb
antivir
antibodi
hypothes
sever
virus
includ
vesicular
stomat
viru
solubl
g
respiratori
syncyti
viru
secret
g
demonstr
rsv
secret
g
absorb
antig
antibodi
interfer
neutral
antibodydepend
cellmedi
viru
clearanc
howev
observ
ebov
sgp
compet
antibodi
mice
immun
sgp
led
us
hypothes
sgp
may
serv
role
alter
repertoir
epitop
host
immun
respons
direct
order
divert
host
immun
respons
toward
epitop
share
sgp
test
hypothesi
vaccin
mice
ratio
fig
simul
antigen
express
ebov
infect
control
group
immun
either
sgpedit
plu
empti
pcagg
vector
keep
total
amount
dna
constant
proxi
vivo
antigen
express
hela
cell
transfect
correspond
ratio
sgpedit
pcagg
measur
western
blot
analysi
level
sgp
express
lysat
cultur
supernat
cell
cotransfect
sgpedit
similar
cell
transfect
sgpedit
alon
fig
immun
group
gener
similar
titer
antibodi
fig
howev
perform
competit
elisa
use
antisera
sgpedit
mice
sgp
abl
compet
antibodi
fig
mice
immun
sgpeditvector
display
serum
reactiv
pattern
observ
previous
mice
immun
one
gp
isoform
boost
mice
second
time
almost
week
antisera
sgpedit
mice
absorb
sgp
interestingli
mice
immun
lower
ratio
signific
sgp
crossreact
also
observ
almost
antibodi
suscept
competit
mice
immun
ratio
suscept
competit
mice
immun
ratio
figur
similar
result
also
obtain
competit
immunoprecipit
assay
shown
fig
antiserum
mice
abl
precipit
sgp
increas
concentr
sgp
attenu
amount
precipit
furthermor
antiserum
abl
effect
neutral
pseudoviru
infect
fig
addit
exogen
sgp
almost
complet
inhibit
pseudoviru
neutral
fig
indic
sgp
effect
interfer
antibodi
mediat
neutral
mice
similar
observ
also
made
antiserum
concentr
correspond
neutral
fig
taken
togeth
data
confirm
sgp
direct
host
antibodi
respons
focu
epitop
share
sgp
therebi
allow
sgp
compet
antibodi
interfer
antibodymedi
viru
neutral
furthermor
observ
sgp
compet
greater
proport
antibodi
week
antisera
compar
week
suggest
iter
exposur
sgp
gradual
drive
host
dominantli
sgpreactiv
respons
order
test
hypothesi
express
sgp
modul
antibodi
respons
prime
boost
mice
either
sgpedit
boost
week
opposit
gp
isoform
fig
control
group
boost
gp
isoform
shown
fig
antibodi
induc
group
week
howev
mice
immun
boost
sgpedit
sgp
abl
effici
compet
antibodi
competit
elisa
fig
furthermor
sgp
also
abl
effici
compet
antibodi
mice
prime
sgpedit
boost
next
investig
whether
sgp
abl
interfer
viru
neutral
sera
cross
prime
boost
mice
shown
fig
sgp
abl
interfer
neutral
anim
prime
sgp
boost
hand
antisera
anim
prime
boost
sgp
maintain
neutral
activ
presenc
sgp
probe
observ
compar
antisera
titer
correspond
neutral
activ
group
week
week
boost
opposit
gp
isoform
shown
fig
neutral
activ
boost
immun
opposit
gp
isoform
thu
appear
sgp
overwhelm
respons
also
boost
nonneutr
antibodi
induc
observ
sgp
alter
reactiv
profil
respons
import
implic
ebov
vaccinolog
sinc
infect
sgp
could
subvert
immun
respons
previous
vaccin
individu
viru
clear
rapidli
role
sgp
ebov
host
immun
evas
clearli
defin
studi
analyz
antibodi
respons
mice
immun
sgp
gp
isoform
present
evid
sgp
serv
redirect
immun
respons
toward
epitop
either
present
inaccess
epitop
share
two
gp
isoform
therebi
allow
sgp
effect
absorb
antibodi
term
phenomenon
antigen
subvers
distinct
previous
propos
mechan
sgp
passiv
absorb
antiglycoprotein
antibodi
antigen
subvers
abil
sgp
absorb
antibodi
critic
depend
exposur
sgp
induct
immun
respons
mice
immun
presenc
sgp
immun
strategi
design
simul
antigen
exposur
natur
infect
observ
result
antibodi
cross
reactiv
thu
suscept
competit
sgp
even
though
titer
antibodi
mice
similar
titer
mice
immun
alon
hand
mice
immun
alon
observ
low
crossreact
antibodi
sgp
find
consist
previou
studi
indic
antibodi
mice
larg
direct
epitop
share
sgp
model
propos
mechan
antigen
subvers
sgp
assum
immun
host
begin
repertoir
bcell
recogn
epitop
distribut
throughout
sgp
fig
howev
sgp
gener
much
higher
quantiti
bcell
recogn
sgp
epitop
epitop
share
sgp
like
encount
cognat
antigen
compar
bcell
recogn
epitop
furthermor
sgpreactiv
bcell
popul
expand
outcompet
bcell
antigen
surviv
signal
thu
humor
respons
skew
toward
sgp
epitop
share
sgp
antigen
subvers
repres
novel
viral
escap
strategi
similar
origin
antigen
sin
oa
classic
oa
initi
exposur
pathogen
result
popul
memori
bcell
recogn
antigen
specif
pathogen
strain
upon
subsequ
exposur
differ
strain
pathogen
crossreact
memori
bcell
respond
preferenti
produc
antibodi
high
affin
initi
pathogen
may
bind
new
strain
effect
furthermor
memori
bcell
compet
antigen
surviv
signal
bcell
might
otherwis
produc
higher
affin
protect
antibodi
new
strain
similarli
overexpress
ebola
viru
sgp
ensur
sgpreactiv
bcell
preferenti
expand
outcompet
bcell
antigen
surviv
signal
result
suboptim
host
respons
direct
away
membranebound
virion
surfac
howev
unlik
classic
oa
process
requir
tempor
separ
antigen
encount
also
occur
simultan
exposur
two
partli
ident
antigen
model
antigen
subvers
also
explain
antibodi
anim
prime
sgp
boost
maintain
crossreact
sgp
anim
prime
sgp
elicit
antibodi
sgp
epitop
share
fig
anim
boost
memori
bcell
recogn
share
epitop
vastli
outnumb
express
higher
affin
receptor
bcell
recogn
unshar
epitop
thu
antisgp
memori
bcell
preferenti
activ
expand
boost
antisgp
respons
situat
analog
one
previouslyinfect
individu
vaccin
rais
possibl
immun
individu
may
simpli
boost
alreadi
unprotect
antibodi
respons
filoviru
infect
rare
find
suggest
may
necessari
devis
altern
strategi
immun
previouslyinfect
individu
way
specif
boost
respons
avoid
subvers
perhap
strike
find
studi
boost
mice
sgp
could
effect
subvert
respons
render
suscept
competit
sgp
hypothes
major
bcell
activ
mice
immun
direct
epitop
share
sgp
fig
small
popul
activ
bcell
react
sgp
support
observ
even
though
sgp
measur
compet
elisa
immunoprecipit
antibodi
mice
mice
still
develop
low
titer
sgpbind
antibodi
mice
boost
sgp
sgpreactiv
bcell
expand
remain
bcell
recogn
unshar
epitop
shift
antibodi
respons
mostli
mostli
sgpcross
reactiv
furthermor
notabl
neutral
activ
actual
decreas
boost
sgp
despit
increas
overal
antibodi
thu
boost
sgp
augment
nonneut
antibodi
highli
suscept
sgp
competit
exist
neutral
antibodi
previous
induc
mice
maintain
resist
sgp
interfer
situat
analog
one
individu
immun
subsequ
infect
ebov
individu
unabl
rapidli
clear
viru
viru
may
replic
suffici
subvert
host
immun
respons
thu
critic
vaccin
induc
high
enough
titer
antibodi
ensur
viru
clear
abl
effect
subvers
fig
inabl
sgp
compet
antibodi
mice
consist
grow
bodi
evid
point
immunodomin
mucin
domain
highli
glycosyl
region
share
sgp
domain
thought
form
steric
bulki
cloak
shield
put
receptor
bind
domain
host
antibodi
suggest
hiv
env
glycan
shield
role
mucin
domain
play
hostpathogen
interact
complex
previou
studi
indic
region
contain
neutral
infectionenhanc
epitop
mask
epitop
steric
occlus
furthermor
mucin
domain
diverg
region
among
ebov
strain
dispens
mediat
viru
attach
membran
fusion
strongli
suggest
role
protect
function
conserv
region
immun
attack
linear
sequenc
sgp
correspond
put
mucinshield
receptor
bind
domain
rbd
possibl
sgp
work
togeth
mucin
domain
host
antibodi
direct
either
share
epitop
steric
shield
trimer
mucin
domain
cleav
host
cell
acidifi
endosom
along
bound
antibodi
possibl
epitop
share
sgp
may
shield
trimer
support
observ
antisgp
antibodi
sgpimmun
mice
crossreact
despit
fact
sgp
share
linear
sequenc
furthermor
antigen
subvers
allow
sgp
effici
absorb
antibodi
recogn
unshield
share
epitop
import
sgpmediat
antigen
subvers
ehf
pathogenesi
remain
elucid
passiv
immun
studi
polyclon
sera
monoclon
antibodi
reveal
whether
sgpcrossreact
antibodi
fact
less
protect
antibodi
particularli
import
given
passiv
transfer
antiebov
monoclon
antibodi
gain
traction
recent
postexposur
therapeut
sgp
crossreact
turn
correl
impair
viru
clearanc
would
underscor
need
elicit
produc
antisera
monoclon
antibodi
achiev
effect
treatment
ebov
infect
moreov
find
also
suggest
ebov
vaccin
tailor
target
region
share
sgp
particularli
relev
recent
effort
develop
broadlyprotect
vaccin
sinc
studi
center
around
focus
vaccin
conserv
epitop
delet
highli
variabl
region
mucin
domain
sgp
actual
correspond
highli
conserv
region
antibodi
elicit
construct
may
crossreact
sgp
therefor
suscept
sgpmediat
subvers
candid
panfiloviru
vaccin
may
need
focus
region
highli
conserv
unshar
sgp
membraneproxim
subunit
also
great
interest
ebov
vaccinolog
determin
whether
antigen
subvers
correl
success
failur
vaccin
protect
anim
lethal
challeng
may
critic
ebov
vaccin
elicit
long
last
immun
respons
high
enough
antibodi
titer
host
clear
viru
abl
replic
effect
antigen
subvers
possibl
consist
nonhuman
primat
lethal
challeng
experi
surviv
close
correl
mainten
antibodi
titer
threshold
level
lower
antibodi
titer
delay
time
death
much
ebov
vaccinolog
focus
elicit
protect
antibodi
membranebound
glycoprotein
robust
tcell
respons
may
also
improv
vaccin
efficaci
immun
nonhuman
primat
low
dose
gp
nucleoprotein
np
express
recombin
adenovirus
demonstr
elicit
robust
antibodi
tcell
respons
confer
protect
lethal
challeng
importantli
ebovspecif
tcell
shown
reduc
threshold
antibodi
need
protect
recombin
vector
express
ctl
epitop
demonstr
confer
protect
lethal
ebov
challeng
mice
gpspecif
well
nucleoprotein
np
specif
tcell
control
infect
even
adopt
transfer
otherwis
anim
studi
suggest
robust
tcell
respons
may
reduc
threshold
antibodi
need
rapid
viru
clearanc
noteworthi
although
express
sgp
conserv
ebola
virus
sgp
produc
marburg
viru
marv
anoth
member
filovirida
instanc
relat
virus
often
diverg
mechan
employ
surviv
respect
host
exampl
sendai
viru
sev
paramyxoviru
caus
sever
respiratori
tract
infect
rodent
express
v
protein
via
rna
edit
p
gene
v
necessari
vivo
surviv
pathogenesi
sev
though
vdefici
sev
show
defect
replic
vitro
howev
close
relat
human
parainfluenza
viru
type
express
v
even
though
p
gene
display
high
degre
homolog
sev
p
caus
similar
diseas
human
sev
caus
rodent
similarli
secret
gp
observ
marv
like
evolv
altern
strategi
surviv
within
host
precis
relev
antigen
subvers
ebola
vaccinolog
remain
determin
antigen
subvers
repres
novel
eleg
solut
challeng
virus
face
balanc
abil
infect
host
cell
effici
evad
host
immun
surveil
constraint
small
genom
neccessit
pack
great
deal
function
small
space
sgpmediat
subvers
repres
mechan
along
glycandepend
steric
shield
immunodomin
mucin
domain
may
help
ebov
surviv
host
improv
understand
mechan
work
togeth
eventu
open
door
ration
design
vaccin
vaccin
direct
highli
conserv
region
subunit
could
induc
broadli
reactiv
antibodi
also
avoid
potenti
sgpmediat
immun
subvers
vaccin
could
protect
multipl
strain
ebov
includ
strain
yet
identifi
studi
carri
strict
accord
recommend
guid
care
use
laboratori
anim
nation
institut
health
anim
ethic
approv
immun
studi
mice
obtain
institut
anim
care
use
committe
iacuc
emori
univers
anim
studi
perform
approv
institut
anim
care
use
committe
iacuc
emori
univers
femal
balbc
mice
old
purchas
jackson
laboratori
hous
anim
facil
emori
univers
cell
hela
cell
maintain
dulbecco
modifi
eagl
medium
dmem
mediatech
supplement
fetal
bovin
serum
hyclon
thermofish
penicillinstreptomycin
ebola
glycoprotein
construct
base
ebola
zair
strain
zebov
mayinga
subtyp
genbank
access
edit
site
mutant
gener
pbluescript
ii
ks
vector
sitedirect
mutagenesi
use
quickchang
xl
kit
stratagen
construct
subclon
pcagg
mammalian
express
vector
protein
express
carri
transfect
confluent
cell
plate
fugen
hd
roch
per
well
per
manufactur
instruct
detect
h
post
transfect
surfac
express
detect
surfac
biotinyl
follow
immunoprecipit
antiebov
gp
mous
polyclon
antibodi
sdspage
avidinhrp
blot
cell
lysat
harvest
cell
lysi
buffer
cell
cultur
supernat
collect
spun
remov
cell
debri
concentr
centrifug
concentr
cell
lysat
concentr
cell
cultur
supernat
run
sdspage
denatur
condit
follow
probe
antiebov
rabbit
polyclon
antibodi
mutant
zebov
gp
plasmid
dna
immun
experi
prepar
use
endofre
plasmid
mega
kit
qiagen
per
manufactur
instruct
redissolv
pure
endotoxinfre
water
concentr
puriti
verifi
restrict
analysi
spectrophotometri
immun
dna
dilut
steril
pb
filter
steril
femal
balbc
mice
charl
river
laboratori
six
mice
per
group
receiv
dna
intramuscularli
per
immun
anesthet
mice
bled
retroorbit
two
week
immun
serum
sampl
store
use
product
purifi
histidinetag
ha
describ
previous
solubl
histidinetag
sgp
gener
ctermin
addit
singl
histidin
tag
solubl
gener
truncat
transmembran
domain
cytoplasm
tail
recombin
vaccinia
virus
rvv
gener
describ
elsewher
synthes
solubl
histag
sgp
hissgp
well
membranebound
product
purif
hissgp
rvvinfect
cell
supernat
clarifi
purifi
use
prepeas
purif
kit
affymetrix
puriti
recombin
protein
verifi
sdspage
follow
western
blot
coomassi
stain
purifi
hissgp
test
reactiv
preimmun
sera
sera
unvaccin
mice
elisa
western
blot
found
unreact
elisa
flatbottom
immulon
plate
thermo
coat
overnight
hissgp
standard
curv
gener
coat
control
well
known
concentr
mous
igg
plate
wash
pbstween
pbst
block
bsa
incub
duplic
two
hour
antisera
dilut
bsa
plate
wash
incub
pool
anti
igg
subtyp
hrpconjug
goat
antimous
secondari
antibodi
final
wash
plate
develop
tmb
thermo
stop
minut
hcl
plate
read
antibodi
concentr
calcul
use
standard
curv
competit
elisa
perform
modifi
protocol
plate
coat
pool
antisera
dilut
bsa
concentr
correspond
od
anti
elisa
dilut
antisera
mix
decreas
concentr
purifi
hissgp
immedi
ad
well
elisa
develop
describ
competit
calcul
percent
signal
compar
compet
antigen
competit
immunoprecipit
perform
incub
pool
antisera
normal
titer
determin
elisa
ng
purifi
increas
amount
purifi
hissgp
molar
ratio
antisera
incub
hissgp
alon
alon
gp
use
control
well
antisera
incub
presenc
recombin
influenza
ha
sampl
incub
ice
minut
follow
addit
prote
coupl
agaros
bead
thermo
scientif
incub
addit
two
hr
agit
sampl
centrifug
wash
three
time
lysi
buffer
mix
laemmli
sd
sampl
buffer
sampl
heat
minut
use
sdspage
follow
western
blot
analysi
use
antibodi
gainst
sgp
appar
affin
polyclon
antisera
determin
quantit
elisa
use
purifi
igg
immun
anim
igg
purifi
use
melon
gel
thermo
per
manufactur
instruct
puriti
igg
verifi
elisa
coomassi
gel
stain
sinc
quantit
affin
elisa
requir
coat
antigen
incub
increas
dilut
antibodi
coat
antigen
becom
satur
found
high
antibodi
concentr
result
signal
exceed
plate
reader
rang
detect
thu
titrat
amount
coat
antigen
avoid
signal
satur
well
coat
overnight
purifi
hissgp
wash
block
incub
purifi
igg
dilut
bsa
dilut
rang
base
origin
serum
volum
elisa
develop
describ
signal
convert
nm
concentr
igg
comparison
standard
curv
appar
kd
polyclon
sera
calcul
nonlinear
regress
analysi
use
graphpad
prism
result
verifi
manual
analysi
linear
bind
curv
detail
elsewher
ebovgp
pseudotyp
hiv
gener
describ
elsewher
briefli
cotransfect
envdefect
hiv
backbon
zebov
gp
pcagg
vector
use
fugen
hd
roch
supernat
harvest
h
posttransfect
clarifi
filter
use
micron
filter
pseudovirus
titer
infect
cell
express
luciferas
tatactiv
promot
caus
infect
cell
turn
blue
xgal
stain
neutral
assay
perform
describ
elsewher
minor
modif
briefli
pseudovirus
preincub
dilut
heatinactiv
antisera
supplement
heatinactiv
mous
sera
innov
research
total
volum
mous
serum
pseudovirusantiserum
mixtur
ad
confluent
cell
incub
h
viru
infect
neutral
measur
luciferas
report
assay
neutral
measur
decreas
luciferas
express
compar
virusonli
control
perform
competit
neutral
assay
select
fix
antisera
concentr
correspond
either
neutral
activ
dilut
antisera
incub
dilut
purifi
hissgp
solubl
influenza
hemagluttinin
ha
control
genbank
access
antisera
mixtur
mix
pseudoviru
neutral
assay
develop
describ
interfer
neutral
determin
percent
rescu
infect
compar
well
pseudovirusantisera
without
compet
sgp
calcul
formula
virusantibodysgp
virusantibodi
viru
alon
virusantibodi
